Lv3
246 积分 2022-12-29 加入
Interstitial lung disease with antibody–drug conjugates: a real-world pharmacovigilance study based on the FAERS database during the period 2014–2023
4天前
已完结
Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer
13天前
已完结
2013P Repotrectinib in adult and pediatric patients with NTRK+ advanced solid tumors: Updated results from the TRIDENT-1 and CARE trials
1个月前
已关闭
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
7个月前
已完结
Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data
8个月前
已关闭
Treatment-related adverse events of antibody drug-conjugates in clinical trials
9个月前
已完结
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis
10个月前
已完结
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
10个月前
已完结
Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
10个月前
已完结
Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study
10个月前
已完结
皖公网安备34019202002308
